Proto-Oncogene Proteins c-myc
"Proto-Oncogene Proteins c-myc" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Basic helix-loop-helix transcription factors encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis.
| Descriptor ID |
D016271
|
| MeSH Number(s) |
D12.776.260.103.813 D12.776.624.664.700.189 D12.776.660.765 D12.776.930.125.813
|
| Concept/Terms |
Proto-Oncogene Proteins c-myc- Proto-Oncogene Proteins c-myc
- Proto Oncogene Proteins c myc
- myc Proto-Oncogene Product p62
- myc Proto Oncogene Product p62
- Proto-Oncogene Proteins myc
- Proteins myc, Proto-Oncogene
- Proto Oncogene Proteins myc
- myc, Proto-Oncogene Proteins
- p62 c-myc
- p62 c myc
- p62(c-myc)
- Proto-Oncogene Products c-myc
- Proto Oncogene Products c myc
- c-myc Proteins
- c myc Proteins
- myc Proto-Oncogene Proteins
- Proto-Oncogene Proteins, myc
- myc Proto Oncogene Proteins
|
Below are MeSH descriptors whose meaning is more general than "Proto-Oncogene Proteins c-myc".
Below are MeSH descriptors whose meaning is more specific than "Proto-Oncogene Proteins c-myc".
This graph shows the total number of publications written about "Proto-Oncogene Proteins c-myc" by people in this website by year, and whether "Proto-Oncogene Proteins c-myc" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2000 | 1 | 2 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 4 | 1 | 5 |
| 2006 | 2 | 2 | 4 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 2 | 4 |
| 2010 | 1 | 0 | 1 |
| 2011 | 4 | 1 | 5 |
| 2012 | 2 | 1 | 3 |
| 2013 | 3 | 1 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 4 | 6 | 10 |
| 2016 | 3 | 5 | 8 |
| 2017 | 2 | 3 | 5 |
| 2018 | 4 | 3 | 7 |
| 2019 | 1 | 3 | 4 |
| 2020 | 5 | 3 | 8 |
| 2021 | 1 | 2 | 3 |
| 2022 | 2 | 0 | 2 |
| 2023 | 0 | 2 | 2 |
| 2024 | 4 | 1 | 5 |
| 2025 | 2 | 1 | 3 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Proto-Oncogene Proteins c-myc" by people in Profiles.
-
MYC-Targeting PROTACs Lead to Bimodal Degradation and N-Terminal Truncation. ACS Chem Biol. 2025 04 18; 20(4):896-906.
-
Prognostic stratification in DLBCL patients with aberrant MYC gene. Br J Haematol. 2024 Nov; 205(5):1782-1793.
-
Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma. Nat Commun. 2023 05 02; 14(1):2502.
-
Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2022 Mar 01; 28(5):972-983.
-
YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. Blood. 2021 07 08; 138(1):71-85.
-
Long non-coding RNA AFAP1-AS1 accelerates lung cancer cells migration and invasion by interacting with SNIP1 to upregulate c-Myc. Signal Transduct Target Ther. 2021 06 25; 6(1):240.
-
Spliceosome-targeted therapies trigger an antiviral immune response in triple-negative breast cancer. Cell. 2021 01 21; 184(2):384-403.e21.
-
MYC Activity Inference Captures Diverse Mechanisms of Aberrant MYC Pathway Activation in Human Cancers. Mol Cancer Res. 2021 03; 19(3):414-428.
-
Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents. Mol Cancer Res. 2021 02; 19(2):249-260.
-
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Cancer Cell. 2020 05 11; 37(5):720-734.e13.